Adverse Thrombosis Events Could be Production Related

A study published in The New England Journal of Medicine on April 9, 2021, discusses that the cause of the thrombosis in some patients vaccinated with COVID-19 vaccines could be insufficient purification that leads to the emergence of significant quantities of free DNA.

This study concluded by saying, 'Vaccination with ChAdOx1 nCov-19 (AstraZeneca COVID-19 Vaccine (Vaxzevria)) can result in the rare development of immune thrombotic thrombocytopenia mediated by platelet-activating antibodies against PF4, which clinically mimics autoimmune heparin-induced thrombocytopenia.'

However, 'insufficient purification or use of very high doses of target DNA/RNA could result in adverse interaction of a patient’s antibodies that activate thrombocytes with elements of the vaccine itself, including free DNA, and consisting of PF4 factor and heparin or nucleic acid - PF4/DNA and PF4/RNA,' stated the Gamaleya Center in Russia on April 14, 2021.

'Thus, all of the above vaccines based on adenoviral vectors have significant differences in their structure and production technology. Therefore, there is no reason and no justification to extrapolate safety data from one vaccine to safety data from other vaccines,' says the Gamaleya Center.